Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study.
Zhang Xuexian, Wang Ruidong, Ding Yuhan, Li Qingwei, Xiong Feng, Ren Hong, Zhang Jun, Li Wei
{"title":"Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study.","authors":"Zhang Xuexian, Wang Ruidong, Ding Yuhan, Li Qingwei, Xiong Feng, Ren Hong, Zhang Jun, Li Wei","doi":"10.3389/fimmu.2024.1422784","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB-TACE-Len-C) and DEB-TACE-Len for the treatment of unresectable hepatocellular carcinoma (uHCC).</p><p><strong>Methods: </strong>This retrospective study consecutively included uHCC patients who underwent DEB-TACE-Len-C or DEB-TACE-Len treatment at our hospital and Qujing Second People's Hospital from April 2020 to April 2022. In total, 85 patients were enrolled. There were 42 patients in the DEB-TACE-Len-C group and 43 patients in the DEB-TACE-Len group. The disease control rate (DCR), objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups, and the factors influencing OS and PFS were analysed.</p><p><strong>Results: </strong>The ORR, DCR, PFS and OS were significantly greater in the DEB-TACE-Len-C group than in the DEB-TACE-Len group (ORR: 76.2% vs. 46.5%, <i>P</i> = 0.005; DCR: 88.1% vs. 67.8%, <i>P</i> = 0.039; PFS: 10 months vs. 6 months, <i>P <</i>0.0001; OS: 24 months vs. 16 months, <i>P</i> = 0.0038). Multivariate Cox proportional hazard regression analysis revealed that portal tumour thrombus (PVTT) and therapeutic approach were independent factors affecting PFS and OS. There were no statistically significant differences in the incidence of AEs between the two groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>Compared with DEB-TACE-Len, DEB-TACE-Len-C is an effective treatment option that can improve the tumour therapeutic response and prolong the OS and PFS in uHCC patients.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534867/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2024.1422784","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: The purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB-TACE-Len-C) and DEB-TACE-Len for the treatment of unresectable hepatocellular carcinoma (uHCC).
Methods: This retrospective study consecutively included uHCC patients who underwent DEB-TACE-Len-C or DEB-TACE-Len treatment at our hospital and Qujing Second People's Hospital from April 2020 to April 2022. In total, 85 patients were enrolled. There were 42 patients in the DEB-TACE-Len-C group and 43 patients in the DEB-TACE-Len group. The disease control rate (DCR), objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups, and the factors influencing OS and PFS were analysed.
Results: The ORR, DCR, PFS and OS were significantly greater in the DEB-TACE-Len-C group than in the DEB-TACE-Len group (ORR: 76.2% vs. 46.5%, P = 0.005; DCR: 88.1% vs. 67.8%, P = 0.039; PFS: 10 months vs. 6 months, P <0.0001; OS: 24 months vs. 16 months, P = 0.0038). Multivariate Cox proportional hazard regression analysis revealed that portal tumour thrombus (PVTT) and therapeutic approach were independent factors affecting PFS and OS. There were no statistically significant differences in the incidence of AEs between the two groups (P > 0.05).
Conclusion: Compared with DEB-TACE-Len, DEB-TACE-Len-C is an effective treatment option that can improve the tumour therapeutic response and prolong the OS and PFS in uHCC patients.
研究目的本研究旨在比较药物洗脱珠（DEB）经动脉化疗栓塞联合来伐替尼和坎瑞珠单抗（DEB-TACE-Len-C）和DEB-TACE-Len治疗不可切除肝细胞癌（uHCC）的安全性和有效性：这项回顾性研究连续纳入了2020年4月至2022年4月在我院和曲靖市第二人民医院接受DEB-TACE-Len-C或DEB-TACE-Len治疗的uHCC患者。共有 85 名患者入选。DEB-TACE-Len-C组42例，DEB-TACE-Len组43例。比较两组患者的疾病控制率（DCR）、客观反应率（ORR）、总生存期（OS）、无进展生存期（PFS）和不良事件（AEs），并分析影响OS和PFS的因素：DEB-TACE-Len-C组的ORR、DCR、PFS和OS均明显高于DEB-TACE-Len组（ORR：76.2% vs. 46.5%，P = 0.005；DCR：88.1% vs. 67.8%，P = 0.039；PFS：10个月 vs. 6个月，P 0.0001；OS：24个月 vs. 16个月，P 0.0001）：24个月对16个月，P = 0.0038）。多变量考克斯比例危险回归分析显示，门静脉肿瘤血栓（PVTT）和治疗方法是影响PFS和OS的独立因素。两组患者的AEs发生率差异无统计学意义（P>0.05）：结论：与DEB-TACE-Len相比，DEB-TACE-Len-C是一种有效的治疗方案，可改善uHCC患者的肿瘤治疗反应，延长OS和PFS。
期刊介绍：
Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
